<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986192</url>
  </required_header>
  <id_info>
    <org_study_id>PRAIS-1.1-12-12</org_study_id>
    <nct_id>NCT01986192</nct_id>
  </id_info>
  <brief_title>Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study</brief_title>
  <acronym>PRAIS</acronym>
  <official_title>An Efficacy and Safety Study of Ribaroxaban for the Prevention of Deep Vein Thrombosis Recurrence in Patients With Acute Iliofemoral Venous Thrombosis Initially Treated With Thrombolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daegu Catholic University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EINSTEIN program showed that oral rivaroxaban is effective and safe treatment for
      prevention of recurrent venous thrombosis and pulmonary embolism in deep vein thrombosis
      patients and FDA approved the rivaroxaban for prevention and treatment of deep vein
      thrombosis (Nov 2 2012).

      Recently, catheter-directed thrombolysis can significantly reduce post-thrombotic syndrome,
      and more and more centers introduce catheter-directed thrombolysis to treat proximal (i.e,
      iliofemoral) DVT. However, the EINSTEIN program excluded patients with deep vein thrombosis
      if they had been treated with a vena cava filter or a fibrinolytic agent for the current
      episode of thrombosis.

      Although catheter-directed thrombolysis (CDT) or pharmacomechanical thrombolysis has now been
      accepted as a treatment of choice in iliofemoral DVT, thrombolysis has an inherent risk of
      bleeding. Therefore, patients who have completed CDT and have been stabilized at least 24
      hours after thrombolysis will be included in this study.

      Also, the investigators want to explore the efficacy and safety of rivaroxaban in patients
      with iliofemoral DVT after catheter-directed thrombolysis and/or a vena cava filter insertion
      and/or venous stent insertion and compare these outcomes with warfarin treatment alone.

      This study will be a pilot study to establish the safety and efficacy parameters for further
      studies.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>six month</time_frame>
    <description>to compare recurrence rate within 6 months after thrombolysis in iliofemoral deep vein thrombosis with warfarin prophylaxis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vascular events</measure>
    <time_frame>six months</time_frame>
    <description>All-cause mortality, vascular events (acute coronary syndrome, ischemic stroke, transient ischemic attack or systemic embolism)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Ileofemoral Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <arm_group_label>rivaroxaban</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Onset of symptoms within the past 21 days

          -  Objectively verified (by CT venography) deep vein thrombosis localized in the
             iliofemoral segment

          -  Complete catheter-directed thrombolysis and/or a vena cava and/or venous stent
             insertion

          -  Informed consent

        Exclusion Criteria:

          -  Incomplete catheter-directed thrombolysis

          -  If patients received more than a single dose of a warfarin before randomization

          -  contraindicating anticoagulant treatment

          -  another indication for a warfarin

          -  an estimated glomerular filtration rate by MDRD equation &lt;30ml/min

          -  clinically significant liver disease (acute hepatitis, chronic active hepatitis,
             cirrhosis)

          -  Alanine aminotransferase &gt; 3-time higher than upper limit of the normal range

          -  Bacterial endocarditis

          -  Active bleeding or high risk of bleeding

          -  Pregnancy or breast-feeding

          -  Concomitant use of strong cytochrome P-450 3A4 inhibitors or inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Kee Min, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Kee Min, MD</last_name>
    <phone>02-2072-0297</phone>
    <email>skminmd@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-il Min, MD</last_name>
      <phone>02-2072-2330</phone>
      <email>surgeonmsi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seung-Kee Min</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>pharmacomechanical thrombolysis</keyword>
  <keyword>aspiration thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

